Seaside Therapeutics LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Seaside Therapeutics LLC
The latest drug development news and highlights from our FDA Performance Tracker.
Alcobra CEO Yaron Daniely admits that drug development for attention deficit hyperactivity disorder (ADHD) is a "road well-traveled," but says his Tel Aviv, Israel-based company is forging a new path and will confirm the efficacy of its drug metadoxine (MDX) around the end of September.
The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.
Using stem cells, researchers have shown that the gene mutation that causes fragile X leads to gene silencing through the binding of a small repeat mRNA transcript to the gene itself. They further show that a small molecule can disrupt this RNA-DNA duplex, preventing the disease from occurring and suggesting a potential prenatal therapy.
- Drug Discovery Tools